Exhibit 99.1

 

 

Biostage Reports First Quarter 2019 Financial Results

 

-        Preparing to file first IND in Q3 2019

 

 

Holliston, MA – May 14, 2019 – Biostage, Inc.

(OTCQB: BSTG) (“Biostage” or the “Company”), a biotechnology company developing bioengineered organ implants to treat life-threatening conditions of the esophagus, bronchus and trachea, today announced its financial results for the three months ended March 31, 2019.

 

Biostage is focused on preparing to file its first Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in the third quarter, seeking approval to start a Phase 1 clinical trial for the Company’s pioneering Cellspan™ Esophageal Implant (CEI) product candidate.

 

Company CEO Jim McGorry commented, “Operationally, we had a strong first quarter of 2019 and are confident in our growing body of data to support our IND filing in esophageal disease in the coming months. We’ve been meeting with key thought leaders in the field at leading institutions as we do the necessary legwork to lay the foundation for our planned clinical trials. Physician feedback has been positive and continues to shape our development. Our pre-clinical and clinical results continue to show that our Cellspan implant stimulates a positive wound healing response in the patient and enables the body to reconstruct short-segment gaps in the esophagus with a regenerative tissue response.”

 

McGorry also noted the pattern of consistency among the Company’s preclinical studies and highlighted Biostage CSO Dr. William Fodor’s recent presentation at a major industry meeting where he discussed the successful first use of a CEI in a human by the Mayo Clinic in 2017. He stated, “The meeting hosted in Madrid by the Alliance for Regenerative Medicine this past April was a great opportunity for Dr. Fodor to talk about the science behind our groundbreaking technology. As he discussed in that presentation, the pattern and timing of regeneration has been consistent between our juvenile piglet model for esophageal atresia, the pig model for esophageal disease, and the 75-year-old human treated at Mayo Clinic.”

 

A recording of Dr. Fodor’s presentation at the Meeting on the Med, including details about the Mayo Clinic patient, is available to view on the Company’s Twitter page

 

 

 

 

 

McGorry added, “Product readiness and clinical evidence support our upcoming IND filing — everything we’ve been working on for the past several years has led up to this moment, so it’s an exciting time for Biostage.”

 

Mr. McGorry also reiterated the vital role offered by the Company’s strategic investors in Asia and the U.S., stating the Company is “fortunate to have such key relationships” with its financial backers. The Company’s financial investors have extensive relationships in Asia and the Company is currently working to establish its business in China, where esophageal cancer incidence is approximately 15 times greater than in the United States.

 

Summary of Financial Results

 

For the three months ended March 31, 2019, the Company reported a net loss of approximately $1.9 million, or a net loss per share of $0.32, compared to a net loss of approximately $1.5 million, or a net loss per share of $0.56 for the three months ended March 31, 2018. The $0.4 million year-over-year increase in net loss was attributable primarily to a $0.5 million increase in research and development costs and a $0.1 million decrease in non-cash expense from change in the fair value of warrants.

 

The Company also recognized grant income for qualified expenditures from a Fast-Track Small Business Innovation Research (SBIR) grant of $114,000 and $59,000 for the three months ended March 31, 2019 and March 31, 2018, respectively.

 

Balance Sheet and Cash

 

At March 31, 2019, the Company had cash on-hand of $1.1 million and no debt. The Company used net cash in operations of approximately of $1.2 million during the quarter ended March 31, 2019.

 

During the three months ended March 31, 2019, the Company also issued 500,000 shares of common stock to an investor in connection with the exercise of a portion of warrants that were issued on December 27, 2017. Such warrants were exercised in exchange for an aggregate cash exercise price of $1.0 million. Subsequent to the end of the quarter, the Company issued an additional 500,000 shares of common stock to the same investor in exchange for warrant exercises. Such warrants were exercised in exchange for an aggregate cash exercise price of $1.0 million.

 

First Quarter Operating Highlights

 

During the first quarter of 2019, the Company advanced its operating programs aimed at bringing its potentially life-changing Cellframe™ technology to underserved patient populations. During the quarter, the Company:

 

·Announced that Dennis Wigle, M.D., Ph.D, chair of thoracic surgery at Mayo Clinic in Rochester, Minnesota, detailed for the first time a single-patient case report that describes the use of a Biostage Cellspan Esophageal Implant to repair the patient's esophagus following esophageal reconstruction associated with the removal of a tumor mass in the chest. Dr. Wigle announced the details speaking at the Tech-Con 2019 meeting hosted by the Society of Thoracic Surgeons on January 26, 2019.

 

 

 

 

Call-in Information

 

Biostage will be hosting a conference call and webcast today at 9:00 am ET to review its operational progress and financial report. On that call, management may respond to questions from the audience and provide information on any of a number of topics related to the business.

 

To participate in the call, please dial (877) 407-8293 (domestic) or (201) 689-8349 (international). The live audio webcast will be accessible on the Events page of the Investors section on the Company's website at www.biostage.com, and will be archived for 60 days. An audio webcast will be available for one week following the call and can be accessed during that period by dialing (877) 660-6853 (domestic) or (201) 612-7415 (international) with Conference ID #: 13690894. 

 

About Biostage, Inc.

 

Biostage is a biotechnology company developing bioengineered organ implants based on its Cellframe technology which combines a proprietary biocompatible scaffold with a patient's own stem cells to create Cellspan organ implants. Cellspan implants are being developed to treat life-threatening conditions of the esophagus, bronchus or trachea with the hope of dramatically improving the treatment paradigm for patients. Based on its preclinical data, Biostage has selected life-threatening conditions of the esophagus as the initial clinical application of its technology.

 

For more information, please visit www.biostage.com and connect with the Company on Twitter and LinkedIn.

 

 

 

 

Forward-Looking Statements:

 

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements in this press release include, but are not limited to, statements relating to effectiveness of the Company's technology, development expectations and regulatory approval of any of the Company’s products, including those utilizing its Cellframe technology, by the U.S. Food and Drug Administration, the European Medicines Agency or otherwise, which expectations or approvals may not be achieved or obtained on a timely basis or at all; or success with respect to any collaborations, clinical trials and other development and commercialization efforts of the Company’s products, including those utilizing its Cellframe technology, which such success may not be achieved or obtained on a timely basis or at all. These statements involve risks and uncertainties that may cause results to differ materially from the statements set forth in this press release, including, among other things, the Company’s ability to obtain and maintain regulatory approval for its products; plus other factors described under the heading "Item 1A. Risk Factors" in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018 or described in the Company’s other public filings. The Company’s results may also be affected by factors of which the Company is not currently aware. The forward-looking statements in this press release speak only as of the date of this press release. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

 

Investor Relations Contact:

Tom McNaughton

Chief Financial Officer

774-233-7300

tmcnaughton@biostage.com

 

 

 

 

BIOSTAGE, INC.

UNAUDITED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value and share data)

 

   March 31,
2019
   December 31,
2018
 
ASSETS          
Current assets:          
Cash  $1,065   $1,305 
Restricted cash   50    50 
Grant receivable   114    176 
Prepaid expenses and other current assets   499    623 
Total current assets   1,728    2,154 
Property, plant and equipment, net   466    479 
Right-of-use assets   143    - 
Total non-current assets   609    479 
Total assets  $2,337   $2,633 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $311   $160 
Accrued and other current liabilities   441    404 
Warrant liability   105    98 
Current portion of operating lease liability   99    - 
Total current liabilities   956    662 
Operating lease liability, net of current portion   44    - 
Total liabilities  $1,000   $662 
           
Stockholders’ equity:          
Undesignated preferred stock, $0.01 par value; 984,000 shares authorized and none issued and outstanding at March 31, 2019 and December 31, 2018  $-   $- 
Common stock, $0.01 par value; 120,000,000 shares authorized at March 31, 2019 and December 31, 2018; 6,169,645 and 5,669,645 shares issued and outstanding as of March 31, 2019 and December 31, 2018, respectively   62    57 
Additional paid-in capital   58,965    57,677 
Accumulated deficit   (57,690)   (55,763)
Total stockholders’ equity   1,337    1,971 
Total liabilities and stockholders’ equity  $2,337   $2,633 

  

 

 

 

BIOSTAGE, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

 

   Three Months Ended
March 31,
 
   2019   2018 
         
Revenues  $-   $- 
           
Operating expenses:          
Research and development   1,034    552 
Selling, general and administrative   1,000    928 
Total operating expenses   2,034    1,480 
           
Operating loss   (2,034)   (1,480)
           
Other income (expense):          
Grant income   114    59 
Change in fair value of warrant liability   (7)   (124)
Total other income (expense), net   107    (65)
           
Net loss  $(1,927)  $(1,545)
           
Basic and diluted net loss per share  $(0.32)  $(0.56)
Weighted average common shares, basic and diluted   6,003    2,751 

 

 

 

 

BIOSTAGE, INC.

UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

 

   Three Months Ended
March 31,
 
   2019   2018 
Cash flows from operating activities          
Net loss  $(1,927)  $(1,545)
Adjustments to reconcile net loss to net cash used in operating activities:          
Share-based compensation expense   293    75 
Depreciation   61    63 
Amortization of right-of-use assets   23    - 
Change in fair value of warrant liability   7    124 
Changes in operating assets and liabilities:          
Grant receivable   62    (59)
Prepaid expenses and other current assets   124    (67)
Accounts payable   127    (698)
Accrued and other current liabilities   37    47 
Lease liabilities   (23)   - 
Net cash used in operating activities   (1,216)   (2,060)
           
Cash flows from investing activities          
Additions to property and equipment   (24)   (3)
Cash received from sale of property, plant and equipment   -    49 
Net cash (used in) provided by investing activities   (24)   46 
           
Cash flows from financing activities          
Return of related party advance   -    (300)
Proceeds from issuance of common stock and warrants, net of offering costs   -    1,095 
Proceeds from exercise of warrants   1,000    - 
Net cash provided by financing activities   1,000    795 
Net decrease in cash and restricted cash   (240)   (1,219)
Cash and restricted cash at beginning of period   1,355    4,038 
Cash and restricted cash at end of period  $1,115   $2,819 
           

 

 

View differences made from one to another to evaluate Biostage, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Biostage, Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

FREE Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue for FREE

Log in with your credentials

or    

Forgot your details?

Create Account